title: Mesenchymal stromal cells promote bowel regeneration after intestinal transplantation: myth to mucosa.
authors.affiliation: The Oxford Transplant Centre, Churchill Hospital, Oxford, UK. carloceresa@hotmail.com.
authors.forename: Carlo D L
authors.initials: CD
authors.lastname: Ceresa
authors.forename: Roger N
authors.initials: RN
authors.lastname: Ramcharan
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Friend
authors.forename: Anil
authors.initials: A
authors.lastname: Vaidya
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007239:Infections / Q000209:etiology* / Q000628:therapy*; D007249:Inflammation; D007413:Intestinal Mucosa / Q000473:pathology*; D007421:Intestine, Small / Q000473:pathology* / Q000502:physiology; D007422:Intestines / Q000637:transplantation*; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000166:cytology*; D008875:Middle Aged; D009468:Neuromuscular Diseases / Q000150:complications / Q000628:therapy; D011183:Postoperative Complications; D012038:Regeneration; D012778:Short Bowel Syndrome / Q000150:complications / Q000628:therapy; D016559:Tacrolimus / Q000627:therapeutic use; D014180:Transplantation / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006680:HLA Antigens; D007166:Immunosuppressive Agents; D000074323:Alemtuzumab; D016559:Tacrolimus